Structure-based drug design of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex
- 31 May 2003
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (14) , 2319-2325
- https://doi.org/10.1016/s0960-894x(03)00410-4
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Metabolic Activation of a Pyrazinone-Containing Thrombin Inhibitor. Evidence for Novel Biotransformation Involving Pyrazinone Ring Oxidation, Rearrangement, and Covalent Binding to ProteinsChemical Research in Toxicology, 2003
- Small, low nanomolar, noncovalent thrombin inhibitors lacking a group to fill the ‘Distal binding pocket’Bioorganic & Medicinal Chemistry Letters, 2003
- Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disordersExpert Opinion on Investigational Drugs, 2001
- INVERSE MAPPING THEOREM ON COORDINATE SPACESBulletin of the London Mathematical Society, 2001
- Crystal Structure of Active Site-Inhibited Human Coagulation Factor VIIa (des-Gla)Journal of Structural Biology, 1999
- Solution-phase chemical library synthesis using polymerassisted purification techniquesCurrent Opinion in Chemical Biology, 1999
- Inhibitory Activity of Unsaturated Fatty Acids and Anacardic Acids toward Soluble Tissue Factor−Factor VIIa ComplexJournal of Natural Products, 1998
- Book reviewAtherosclerosis, 1998
- Initiation of blood coagulation: the tissue factor/factor VIIa complexCurrent Opinion in Biotechnology, 1996
- The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factorNature, 1996